Physician profile
Ashley D Ring
NPI 1336626076
$5,153.12
in general payments reported to CMS, 2019-2025
31 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what 92% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $770 · 2023: $953 · 2024: $1,390 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $741.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $647.56 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $551.02 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $470.08 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $464.46 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $294.50 | 2022-2025 | Dexcom G6 Transmitter |
| Amgen INC. | $252.34 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $246.33 | 2022-2025 | |
| Astellas Pharma US INC | $187.63 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $156.50 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $132.78 | 2021-2023 | Spravato |
| Shield Therapeutics INC | $126.52 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.09 | 2022 | |
| Medtronic, INC. | $97.10 | 2023-2025 | Minimed 780g |
| Abbott Laboratories | $87.73 | 2023-2025 | Freestyle Libre 3, Freestyle Libre |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $77.64 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Eisai INC. | $68.79 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $48.77 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.19 | 2023-2024 | Xifaxan |
| Sumitomo Pharma America, INC. | $44.28 | 2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $43.72 | 2022 | |
| Merck Sharp & Dohme LLC | $43.57 | 2021-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $37.35 | 2023-2024 | Jardiance |
| Antares Pharma, INC. | $24.98 | 2024 | Xyosted |
| Axsome Therapeutics, INC. | $22.73 | 2025 | Auvelity |
| Insulet Corporation | $22.04 | 2024 | Omnipod |
| Kowa Pharmaceuticals America, INC. | $14.28 | 2023 | Seglentis, Livalo |
| Sanofi Pasteur INC. | $14.11 | 2023 | |
| Sanofi-Aventis U.S. LLC | $11.39 | 2021 | |
| Genentech USA, INC. | $9.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Ring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.